Literature DB >> 26309809

Reactive Oxygen Species and Mitochondrial DNA Damage and Repair in BCR-ABL1 Cells Resistant to Imatinib.

Janusz Blasiak1, Grazyna Hoser2, Jolanta Bialkowska-Warzecha3, Elzbieta Pawlowska4, Tomasz Skorski5.   

Abstract

Imatinib revolutionized the therapy of chronic myeloid leukemia (CML), but the resistance to it became an emerging problem. We reported previously that CML cells expressing the BCR/ABL1 fusion gene, accumulated a high level of reactive oxygen species (ROS) due to deregulated mitochondrial electron transport chain, which in turn led to genomic instability, resulting in imatinib resistance. In the present work, we hypothesize that imatinib-resistant cells may show higher instability of mitochondrial DNA (mtDNA) than their sensitive counterparts. To verify this hypothesis, we checked the ROS level and mtDNA damage and repair in model CML cells sensitive and resistant to imatinib and exposed to doxorubicin (DOX), a DNA-damaging agent. The extent of endogenous ROS in imatinib-resistant cells was higher than in their sensitive counterparts and DOX potentiated this relationship. ROS level in cells with primary resistance, which resulted from the T315I mutation in BCR/ABL1, was higher than in cells with acquired resistance. DOX-induced mtDNA damage in T315I imatinib-resistant cells was more pronounced than in imatinib-sensitive cells. All kinds of cells were repairing mtDNA damage with similar kinetics. In conclusion, imatinib-resistant cells can show increased instability of mtDNA, which can result from increased ROS production.

Entities:  

Keywords:  BCR-ABL1; DNA repair; imatinib resistance; mitochondrial DNA damage/repair; reactive oxygen species

Year:  2015        PMID: 26309809      PMCID: PMC4509616          DOI: 10.1089/biores.2015.0022

Source DB:  PubMed          Journal:  Biores Open Access        ISSN: 2164-7844


  35 in total

1.  The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells.

Authors:  M Sattler; S Verma; G Shrikhande; C H Byrne; Y B Pride; T Winkler; E A Greenfield; R Salgia; J D Griffin
Journal:  J Biol Chem       Date:  2000-08-11       Impact factor: 5.157

Review 2.  Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.

Authors:  Justin M Drake; John K Lee; Owen N Witte
Journal:  Mol Cell Biol       Date:  2014-02-24       Impact factor: 4.272

Review 3.  Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia.

Authors:  D Bixby; M Talpaz
Journal:  Leukemia       Date:  2010-11-19       Impact factor: 11.528

4.  Hydrogen peroxide causes significant mitochondrial DNA damage in human RPE cells.

Authors:  S W Ballinger; B Van Houten; G F Jin; C A Conklin; B F Godley
Journal:  Exp Eye Res       Date:  1999-06       Impact factor: 3.467

5.  Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells.

Authors:  Douglas J Kominsky; Jelena Klawitter; Jaimi L Brown; Laszlo G Boros; Junia V Melo; S Gail Eckhardt; Natalie J Serkova
Journal:  Clin Cancer Res       Date:  2009-04-28       Impact factor: 12.531

Review 6.  Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management.

Authors:  Elias Jabbour; Hagop Kantarjian
Journal:  Am J Hematol       Date:  2014-05       Impact factor: 10.047

7.  Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs.

Authors:  Neil Ashley; Joanna Poulton
Journal:  Biochem Biophys Res Commun       Date:  2008-11-24       Impact factor: 3.575

8.  A deletion of mitochondrial DNA in murine doxorubicin-induced cardiotoxicity.

Authors:  K Adachi; Y Fujiura; F Mayumi; A Nozuhara; Y Sugiu; T Sakanashi; T Hidaka; H Toshima
Journal:  Biochem Biophys Res Commun       Date:  1993-09-15       Impact factor: 3.575

9.  DNA base modifications induced in isolated human chromatin by NADH dehydrogenase-catalyzed reduction of doxorubicin.

Authors:  S A Akman; J H Doroshow; T G Burke; M Dizdaroglu
Journal:  Biochemistry       Date:  1992-04-07       Impact factor: 3.162

10.  Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells.

Authors:  Jérome Kluza; Manel Jendoubi; Caroline Ballot; Abir Dammak; Aurélie Jonneaux; Thierry Idziorek; Sami Joha; Véronique Dauphin; Myriam Malet-Martino; Stéphane Balayssac; Patrice Maboudou; Gilbert Briand; Pierre Formstecher; Bruno Quesnel; Philippe Marchetti
Journal:  PLoS One       Date:  2011-07-18       Impact factor: 3.240

View more
  4 in total

Review 1.  Retinal pigment epithelium and age-related macular degeneration: A review of major disease mechanisms.

Authors:  Shreya Somasundaran; Ian J Constable; Carla B Mellough; Livia S Carvalho
Journal:  Clin Exp Ophthalmol       Date:  2020-08-17       Impact factor: 4.207

2.  Relationship between Oxidative Stress and Imatinib Resistance in Model Chronic Myeloid Leukemia Cells.

Authors:  Sylwester Głowacki; Ewelina Synowiec; Marzena Szwed; Monika Toma; Tomasz Skorski; Tomasz Śliwiński
Journal:  Biomolecules       Date:  2021-04-20

Review 3.  Mitochondrial Retinopathies.

Authors:  Massimo Zeviani; Valerio Carelli
Journal:  Int J Mol Sci       Date:  2021-12-25       Impact factor: 5.923

4.  KLF5 controls glutathione metabolism to suppress p190-BCR-ABL+ B-cell lymphoblastic leukemia.

Authors:  Cuiping Zhang; Angelo D'Alessandro; Ashley M Wellendorf; Fatima Mohmoud; Juana Serrano-Lopez; John P Perentesis; Kakajan Komurov; Gabriela Alexe; Kimberly Stegmaier; Jeffrey A Whitsett; H Leighton Grimes; Jose A Cancelas
Journal:  Oncotarget       Date:  2018-07-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.